202 related articles for article (PubMed ID: 34546340)
1. DKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.
Zhang Q; Gong W; Wu H; Wang J; Jin Q; Lin C; Xu S; Bao W; Wang Y; Wu J; Feng S; Zhao C; Chen B; Liu Z
Carcinogenesis; 2021 Oct; 42(10):1223-1231. PubMed ID: 34546340
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
3. DKK1 activates noncanonical NF-κB signaling via IL-6-induced CKAP4 receptor in multiple myeloma.
Li X; Wang J; Zhu S; Zheng J; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Wang M; Wang J; Wang S; Zhong Y; Liu Z
Blood Adv; 2021 Sep; 5(18):3656-3667. PubMed ID: 34470047
[TBL] [Abstract][Full Text] [Related]
4. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
[TBL] [Abstract][Full Text] [Related]
5. Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma.
Choi YW; Park JS; Han JH; Kim JH; Ahn MS; Lee HW; Kang SY; Choi JH; Jeong SH
Leuk Lymphoma; 2018 Nov; 59(11):2670-2678. PubMed ID: 29582699
[TBL] [Abstract][Full Text] [Related]
6. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer.
Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q
Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
[TBL] [Abstract][Full Text] [Related]
8. Positive feedback of SuFu negating protein 1 on Hedgehog signaling promotes colorectal tumor growth.
Yan Z; Cheng M; Hu G; Wang Y; Zeng S; Huang A; Xu L; Liu Y; Shi C; Deng L; Lu Q; Rao H; Lu H; Chen YG; Luo S
Cell Death Dis; 2021 Feb; 12(2):199. PubMed ID: 33608498
[TBL] [Abstract][Full Text] [Related]
9. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
10. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
11. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
[TBL] [Abstract][Full Text] [Related]
12. The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.
Huang X; Gu H; Zhang E; Chen Q; Cao W; Yan H; Chen J; Yang L; Lv N; He J; Yi Q; Cai Z
Int J Cancer; 2020 Apr; 146(7):1963-1978. PubMed ID: 31390487
[TBL] [Abstract][Full Text] [Related]
13. CircRNA ITCH increases bortezomib sensitivity through regulating the miR-615-3p/PRKCD axis in multiple myeloma.
Liu J; Du F; Chen C; Li D; Chen Y; Xiao X; Hou X
Life Sci; 2020 Dec; 262():118506. PubMed ID: 33031827
[TBL] [Abstract][Full Text] [Related]
14. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
[TBL] [Abstract][Full Text] [Related]
15. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
16. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
17. The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation.
Zhu W; He X; Hua Y; Li Q; Wang J; Gan X
J Biol Chem; 2017 Jul; 292(27):11178-11188. PubMed ID: 28500134
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cross-talk between the hedgehog and NF-κB signaling pathways in multiple myeloma.
Cai K; Na W; Guo M; Xu R; Wang X; Qin Y; Wu Y; Jiang J; Huang H
Leuk Lymphoma; 2019 Mar; 60(3):772-781. PubMed ID: 30644322
[TBL] [Abstract][Full Text] [Related]
20. Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance.
Li X; Wang S; Xie Y; Jiang H; Guo J; Wang Y; Peng Z; Hu M; Wang M; Wang J; Li Q; Wang Y; Liu Z
Nat Commun; 2023 Mar; 14(1):1290. PubMed ID: 36894562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]